Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 6/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.58 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.58 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.58 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.58 |
| ▸ | FLT1 | P17948 | 5/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.54 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | BMP4 | P12644 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506836 | 1.00 | NPC1 (0.65) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12158770 | 0.84 | NPC1 (0.65) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL18430928 | 0.84 | NPC1 (0.65) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL19292009 | 0.84 | NPC1 (0.65) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12158775 | 0.82 | NPC1 (0.62) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL17180934 | 0.82 | NPC1 (0.62) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL11898739 | 0.80 | NPC1 (0.97) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL19560190 | 0.80 | LTA4H (0.67) | NPC1RAB9AHRH3LTA4HCA12 | |
| SCHEMBL159594 | 0.79 | NPC1 (0.58) | NPC1RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL10085622 | 0.79 | SRC (0.59) | NPC1RAB9APRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155681-B1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATHENEX INC (US) | 2018-05-02 | — | — | EP | claimed |
| EP-2114934-B1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2015-10-21 | — | — | EP | claimed |
| US-7939529-B2 | Substantially pure 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide salts, solvates, hydrates, prodrugs; hyperproliferative disorders, cancers, pre-cancers, osteoporosis, cardiovascular disorders; bacterial, fungal, parasitic or viral infection | KINEX PHARMACEUTICALS, LLC (US) | 2011-05-10 | — | — | US | claimed |
| EP-2155681-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Kinex Pharmaceuticals, LLC (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008144045-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2008-11-27 | — | — | WO | claimed |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-11-20 | — | — | US | claimed |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATNX SPV LLC (US) | 2024-10-17 | — | — | US | disclosed |
| CN-113999166-B | Synthesis method of tinib bulin | 山东汇海医药化工有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220160672-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-20220160672-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| CN-113999166-A | Synthesis method of tinib bulin | 山东汇海医药化工有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210198202-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-01 | — | — | US | disclosed |
| US-20210198202-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-01 | — | — | US | disclosed |
| WO-2008082637-A9 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008082637-A9 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082637-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082637-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | MAP3K4, MAP3K6, MAP3K3 | NPC1 3753/4885RAB9A 3365/4885PRKAB2 60/4885 |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | MAP3K2, MAP3K6, MAP3K4 | NPC1 4591/4885RAB9A 2750/4885PRKAB2 59/4885 |
| US-20220160672-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K6, MAP3K10 | NPC1 1437/4885RAB9A 1994/4885PRKAB2 65/4885 |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | NPC1 4682/4885RAB9A 2727/4885PRKAB2 71/4885 |
| US-20210198202-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | NPC1 4693/4885RAB9A 2953/4885PRKAB2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.